Equities Research Analysts’ updated eps estimates for Monday, October 9th:

Abeona Therapeutics (NASDAQ:ABEO) had its buy rating reissued by analysts at HC Wainwright.

Citigroup (NYSE:C) had its outperform rating reiterated by analysts at Credit Suisse Group. Credit Suisse Group currently has a $83.00 price target on the stock, up from their previous price target of $73.00. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

Citigroup (NYSE:C) had its hold rating reiterated by analysts at Stifel Nicolaus.

CareDx (NASDAQ:CDNA) had its buy rating reiterated by analysts at Craig Hallum. Craig Hallum currently has a $10.00 price target on the stock, up from their previous price target of $4.00.

DXC Technology Company. (NYSE:DXC) had its overweight rating reiterated by analysts at KeyCorp. They currently have a $99.00 target price on the stock, up from their previous target price of $92.00.

Envestnet (NYSE:ENV) had its average rating reaffirmed by analysts at UBS AG. UBS AG currently has a $63.00 target price on the stock, up from their previous target price of $50.00.

Express Scripts Holding (NASDAQ:ESRX) had its underperform rating reissued by analysts at Raymond James Financial, Inc..

J P Morgan Chase & Co (NYSE:JPM) had its outperform rating reissued by analysts at Credit Suisse Group. Credit Suisse Group currently has a $110.00 price target on the stock, up from their previous price target of $103.00. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

Juno Therapeutics (NASDAQ:JUNO) had its buy rating reiterated by analysts at Maxim Group. The firm currently has a $56.00 target price on the stock, up from their previous target price of $34.00. The analysts wrote, “The past few months have been transformative for the CAR-T space as Novartis’ Kymriah was approved and Gilead’s (GILD – $82.14 – Hold) (formerly Kite’s) axi-cel is likely to be approved in coming weeks. Gilead paid $12B for Kite, and Novartis has set the pricing bar for CAR-T at $475K. CAR-T is likely to be a multi-billion dollar global market opportunity, and that’s just for end- stage blood cancers. The question is if Kite sold for $12B, what’s the potential for Juno? The company is not far behind clinically as JCAR017’s TRANSCEND study will become a registration study and Juno could have its first CAR on the market in 2019.””

Kinsale Capital Group (NASDAQ:KNSL) had its buy rating reaffirmed by analysts at SunTrust Banks, Inc.. SunTrust Banks, Inc. currently has a $50.00 target price on the stock. They noted that the move was a valuation call. The analysts noted that the move was a valuation call.

New Residential Investment Corp. (NYSE:NRZ) had its buy rating reissued by analysts at FBR & Co. They currently have a $17.50 price target on the stock. The analysts wrote, “Last week, we hosted a series of meetings with Michael Nierenberg, CEO of NRZ, Nick Santoro, CFO, and Mandy Cheuk, investor relations. The tone of the meetings was positive, with the biggest question being: What does the future hold for NRZ? As legacy residential product is becoming relatively harder to come by, and today’s asset prices are pretty full, management noted that it is happy to remain on the sidelines while it identifies opportunities that would protect and enhance its existing portfolio. Overall, we believe that this is the right strategy at the moment, especially as we estimate that NRZ can comfortably cover its $0.50 quarterly dividend per share in the medium term. That said, should investment opportunities arise, the company is well positioned, from a liquidity perspective, to take advantage of them.””

Provident Financial plc (LON:PFG) had its buy rating reiterated by analysts at Numis Securities Ltd. The firm currently has a GBX 1,097 ($14.55) target price on the stock.

K&S AG (ETR:SDF) had its neutral rating reiterated by analysts at DZ Bank AG.

Ten Entertainment Group PLC (LON:TEG) had its buy rating reiterated by analysts at Numis Securities Ltd. They currently have a GBX 215 ($2.85) price target on the stock.

Trinity Mirror plc (LON:TNI) had its buy rating reissued by analysts at Numis Securities Ltd. Numis Securities Ltd currently has a GBX 210 ($2.79) target price on the stock.

UNITE Group plc (LON:UTG) had its add rating reaffirmed by analysts at Numis Securities Ltd. They currently have a GBX 776 ($10.29) price target on the stock.

Viacom (NASDAQ:VIA) had its sell rating reaffirmed by analysts at Citigroup Inc..

Receive News & Stock Ratings for Abeona Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc and related stocks with our FREE daily email newsletter.